Tenax Therapeutics Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against Tenax Therapeutics, targeting investors who bought TENX shares over a nearly three-year window.
Law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, with a lead plaintiff deadline set for December 28, 2026.
Investors who purchased TENX securities between November 13, 2023, and August 7, 2026, may be eligible to recover losses incurred during that period, according to the firm's announcement. The roughly three-year class period suggests the alleged misconduct spans a significant stretch of the company's recent trading history.
Read more Kansas City Life Insurance Posts Lower Q3 2026 Earnings →
The lawsuit, filed in New York, seeks to recover damages on behalf of affected shareholders. Securities class actions of this type typically allege that a company or its executives made materially false or misleading statements that artificially inflated the stock price, causing investor losses when the truth emerged — though the specific allegations in this case were not detailed in the initial announcement.
Shareholders who believe they qualify as lead plaintiff have until the December 2026 deadline to come forward. Lead plaintiffs in class actions generally must demonstrate they suffered the largest financial loss among class members and are able to adequately represent the broader group of investors.
Continue reading at All Financial Services & Investing
